Lionco(SH:603669) Shang Hai Zheng Quan Bao·2025-08-22 21:42Core Viewpoint - The company, Lingkang Pharmaceutical, has released its 2025 semi-annual report, confirming no profit distribution or capital reserve transfer during this period, and ensuring the report's authenticity and completeness [3][5][19]. Group 1: Company Overview - Lingkang Pharmaceutical Group Co., Ltd. is identified by the stock code 603669 and is publicly traded [5]. - The company has confirmed that all board members attended the board meeting where the semi-annual report was approved [1][6]. Group 2: Financial Data - The semi-annual report is unaudited, and the company has not made any profit distribution or capital reserve transfer during the reporting period [2][3]. - The company reported a total of 70,294.97 million RMB in net funds raised from its initial public offering in 2015, after deducting various fees [20][21]. Group 3: Fund Management - The company has established dedicated accounts for managing raised funds, ensuring compliance with relevant laws and regulations [24][25]. - As of June 30, 2025, the company has utilized 70,232.36 million RMB of the raised funds for various projects, including production line construction and working capital [26]. Group 4: Special Reports - The board and supervisory committee have approved a special report on the use of raised funds, confirming that the funds have been managed and utilized according to established protocols [10][17]. - The company has temporarily supplemented working capital with idle raised funds, amounting to 28,991.40 million RMB as of June 30, 2025 [30].